Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

4(44.4%)

Phase 2

3(33.3%)

Phase 4

1(11.1%)

N/A

1(11.1%)

9Total

Phase 3(4)

Phase 2(3)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04125836Phase 3Completed

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Role: lead

NCT05281328Phase 2Active Not Recruiting

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Role: lead

NCT05050942Phase 3Active Not Recruiting

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Role: lead

NCT04076462Phase 3Completed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Role: lead

NCT02946073Phase 3Completed

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain

Role: collaborator

NCT02299089Phase 2Completed

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Role: lead

NCT02212197Phase 2Completed

Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer

Role: lead

NCT01684566Not ApplicableCompleted

A Comparative Investigation of Standard Of Care (SOC) and Episil® in Combination Versus SOC Alone on Oral Mucositis

Role: lead

NCT01316393Phase 4Completed

Effects of Mucoprotective Product on Xerostomia

Role: lead

All 9 trials loaded